Long-term Safety and Efficacy of Subcutaneous Immunoglobulin IgPro20 in CIDP: The PATH Extension Study

被引：0
|
作者：
Mielke, Orell [1 ]
van Schaik, Ivo [2 ]
Bril, Vera [3 ]
van Geloven, Nan [4 ]
Hartung, Hans-Peter [5 ]
Lewis, Richard [6 ]
Sobue, Gen [7 ]
Lawo, John-Philip [1 ]
Praus, Michaela [1 ]
Durn, Billie [1 ]
Cornblath, David [8 ]
Merkies, Ingemar [9 ]
机构：
[1] CSL Behring, King Of Prussia, PA USA
[2] Univ Amsterdam, Amsterdam, Netherlands
[3] Univ Toronto, Toronto, ON, Canada
[4] Leiden Univ, Med Ctr, Leiden, Netherlands
[5] Heinrich Heine Univ, Dusseldorf, Germany
[6] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[7] Nagoya Univ, Nagoya, Aichi, Japan
[8] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[9] Maastricht Univ, Med Ctr, Maastricht, Netherlands
来源：
ANNALS OF NEUROLOGY | 2018年 / 84卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
M275
引用
收藏
页码：S218 / S218
页数：1
相关论文
共 50 条
  • [1] Long-term Safety and Efficacy of Subcutaneous Immunoglobulin IgPro20 in CIDP: the PATH Extension Study
    van Schaik, Ivo N.
    Mielke, Orell
    Bril, Vera
    van Geloven, Nan
    Hartung, Hans-Peter
    Lewis, Richard A.
    Sobue, Gen
    Lawo, John-Philip
    Praus, Micheala
    Durn, Billie L.
    Cornblath, David R.
    Merkies, Ingemar S. J.
    NEUROLOGY, 2019, 92 (15)
  • [2] Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP PATH extension study
    van Schaik, Ivo N.
    Mielke, Orell
    Bril, Vera
    van Geloven, Nan
    Hartung, Hans-Peter
    Lewis, Richard A.
    Sobue, Gen
    Lawo, John-Philip
    Praus, Michaela
    Durn, Billie L.
    Cornblath, David R.
    Merkies, Ingemar S. J.
    Sabet, A.
    George, K.
    Roberts, L.
    Carne, R.
    Blum, S.
    Henderson, R.
    Van Damme, P.
    Demeestere, J.
    Larue, S.
    D'Amour, C.
    Bril, V
    Breiner, A.
    Kunc, P.
    Michal, V
    Sussova, J.
    Tomas, K.
    Talab, R.
    Michal, B.
    Toomsoo, T.
    Rubanovits, I
    Gross-Paju, K.
    Sorro, U.
    Saarela, M.
    Auranen, M.
    Pouget, J.
    Attarian, S.
    Le Masson, G.
    Wielanek-Bachelet, A.
    Desnuelle, C.
    Delmont, E.
    Clavelou, P.
    Aufauvre, D.
    Schmidt, J.
    Zschumtszsch, J.
    Sommer, C.
    Kramer, D.
    Hoffmann, O.
    Goerlitz, C.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (05):
  • [3] Long-term safety and efficacy of subcutaneous imunoglobulin IgPro20 in CIDP: The PATH extension study
    van Schaik, Ivo
    Mielke, Orell
    Bril, Vera
    van Geloven, Nan
    Hartung, Hans-Peter
    Lewis, Richard
    Sobue, Gen
    Lawo, John-Philip
    Praus, Michaela
    Durn, Billie
    Cornblath, David
    Merkies, Ingemar
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 294 - 295
  • [4] Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
    Kanegane, Hirokazu
    Imai, Kohsuke
    Yamada, Masafumi
    Takada, Hidetoshi
    Ariga, Tadashi
    Bexon, Martin
    Rojavin, Mikhail
    Hu, Wilson
    Kobayashi, Midori
    Lawo, John-Philip
    Nonoyama, Shigeaki
    Hara, Toshiro
    Miyawaki, Toshio
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (02) : 204 - 211
  • [5] Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
    Hirokazu Kanegane
    Kohsuke Imai
    Masafumi Yamada
    Hidetoshi Takada
    Tadashi Ariga
    Martin Bexon
    Mikhail Rojavin
    Wilson Hu
    Midori Kobayashi
    John-Philip Lawo
    Shigeaki Nonoyama
    Toshiro Hara
    Toshio Miyawaki
    Journal of Clinical Immunology, 2014, 34 : 204 - 211
  • [6] Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
    John B. Hagan
    Mary B. Fasano
    Sheldon Spector
    Richard L. Wasserman
    Isaac Melamed
    Mikhail A. Rojavin
    Othmar Zenker
    Jordan S. Orange
    Journal of Clinical Immunology, 2010, 30 : 734 - 745
  • [7] Correlation between serum IgG levels and INCAT scores in patients with CIDP receiving subcutaneous immunoglobulin (IgPro20) in the PATH study
    Ma, X.
    Cornblath, D. R.
    Yuraszeck, T.
    Mielke, O.
    Bril, V.
    Hartung, H. -P.
    Sobue, G.
    Lawo, J. -P.
    Praus, M.
    Durn, B. L.
    Lewis, R. A.
    Merkies, I.
    Van Schaik, I. N.
    Tortorici, M. A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 93 - 93
  • [8] Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients with Primary Immunodeficiency
    Hagan, J.
    Fasano, M. B.
    Spector, S.
    Wasserman, R. L.
    Melamed, I.
    Rojavin, M. A.
    Zenker, O.
    Orange, J. S.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB140 - AB140
  • [9] Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
    Hagan, John B.
    Fasano, Mary B.
    Spector, Sheldon
    Wasserman, Richard L.
    Melamed, Isaac
    Rojavin, Mikhail A.
    Zenker, Othmar
    Orange, Jordan S.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2010, 30 (05) : 734 - 745
  • [10] Erratum to: Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
    Hirokazu Kanegane
    Kohsuke Imai
    Masafumi Yamada
    Hidetoshi Takada
    Tadashi Ariga
    Martin Bexon
    Mikhail Rojavin
    Wilson Hu
    Midori Kobayashi
    John-Philip Lawo
    Shigeaki Nonoyama
    Toshiro Hara
    Toshio Miyawaki
    Journal of Clinical Immunology, 2014, 34 : 520 - 520
12345